TECON BIOLOGY Co.LTD (SHE:002100)
China · Delayed Price · Currency is CNY 6.60
+0.02 (0.30%)
May 29, 2026, 3:04 PM CST
TECON BIOLOGY Co.LTD Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 16,660 | 16,924 | 17,114 | 18,973 | 16,958 | 15,663 |
Other Revenue | 57.23 | 57.23 | 62.23 | 52.75 | 31.07 | 47.43 |
| 16,718 | 16,981 | 17,176 | 19,026 | 16,989 | 15,711 | |
Revenue Growth (YoY) | -4.90% | -1.13% | -9.72% | 11.99% | 8.14% | 31.07% |
Cost of Revenue | 15,430 | 15,350 | 15,103 | 18,965 | 15,375 | 14,595 |
Gross Profit | 1,288 | 1,631 | 2,073 | 61.29 | 1,615 | 1,116 |
Selling, General & Admin | 879.64 | 898.5 | 989.66 | 1,030 | 971.45 | 1,340 |
Research & Development | 168.08 | 181.02 | 194.2 | 252.85 | 176.38 | 167.89 |
Other Operating Expenses | 57.9 | 49.63 | 45.81 | 46.8 | 38.72 | 38.33 |
Operating Expenses | 1,145 | 1,169 | 1,306 | 1,347 | 1,237 | 1,570 |
Operating Income | 142.58 | 462.07 | 766.51 | -1,286 | 377.63 | -454.1 |
Interest Expense | -160 | -160 | -178.94 | -245.54 | -248.55 | -206.09 |
Interest & Investment Income | 58.16 | 58.05 | 38.64 | 60.94 | 64.94 | 46.99 |
Currency Exchange Gain (Loss) | -0.05 | -0.05 | -0 | - | - | - |
Other Non Operating Income (Expenses) | -117.97 | -94.62 | -47.9 | -39.41 | -5.87 | -1.9 |
EBT Excluding Unusual Items | -77.27 | 265.45 | 578.31 | -1,510 | 188.14 | -615.1 |
Impairment of Goodwill | - | - | -12.66 | -9.58 | - | - |
Gain (Loss) on Sale of Investments | 9.1 | 0.81 | -1.87 | -0 | 0.94 | - |
Gain (Loss) on Sale of Assets | 1.62 | 0.59 | 4.5 | 3.9 | 0.23 | -36.72 |
Asset Writedown | -34.3 | -31.47 | -28.91 | -34.12 | -0.06 | -48.63 |
Other Unusual Items | 92.73 | 92.73 | 71.44 | 56.63 | 26.79 | 37 |
Pretax Income | -8.11 | 328.11 | 610.81 | -1,493 | 216.03 | -663.45 |
Income Tax Expense | 35.53 | 27.8 | 14.39 | 23.46 | 26.03 | 31.9 |
Earnings From Continuing Operations | -43.64 | 300.31 | 596.42 | -1,516 | 190 | -695.35 |
Minority Interest in Earnings | -57.15 | -89.67 | 8.63 | 153.11 | 90.78 | -7.45 |
Net Income | -100.79 | 210.63 | 605.05 | -1,363 | 280.78 | -702.79 |
Net Income to Common | -100.79 | 210.63 | 605.05 | -1,363 | 280.78 | -702.79 |
Net Income Growth | - | -65.19% | - | - | - | - |
Shares Outstanding (Basic) | 1,408 | 1,404 | 1,375 | 1,350 | 1,337 | 1,098 |
Shares Outstanding (Diluted) | 1,408 | 1,404 | 1,375 | 1,350 | 1,337 | 1,098 |
Shares Change (YoY) | 2.46% | 2.12% | 1.88% | 0.95% | 21.76% | 2.13% |
EPS (Basic) | -0.07 | 0.15 | 0.44 | -1.01 | 0.21 | -0.64 |
EPS (Diluted) | -0.07 | 0.15 | 0.44 | -1.01 | 0.21 | -0.64 |
EPS Growth | - | -65.91% | - | - | - | - |
Free Cash Flow | 645.71 | 1.91 | 535.4 | 750.48 | -1,102 | -219.37 |
Free Cash Flow Per Share | 0.46 | 0.00 | 0.39 | 0.56 | -0.82 | -0.20 |
Dividend Per Share | 0.078 | 0.078 | 0.220 | - | 0.220 | - |
Dividend Growth | -64.55% | -64.55% | - | - | - | - |
Gross Margin | 7.70% | 9.60% | 12.07% | 0.32% | 9.50% | 7.11% |
Operating Margin | 0.85% | 2.72% | 4.46% | -6.76% | 2.22% | -2.89% |
Profit Margin | -0.60% | 1.24% | 3.52% | -7.17% | 1.65% | -4.47% |
Free Cash Flow Margin | 3.86% | 0.01% | 3.12% | 3.94% | -6.49% | -1.40% |
EBITDA | 781.67 | 1,116 | 1,478 | -482.87 | 1,091 | 250.85 |
EBITDA Margin | 4.68% | 6.57% | 8.60% | -2.54% | 6.42% | 1.60% |
D&A For EBITDA | 639.09 | 653.49 | 711.1 | 802.92 | 713.19 | 704.95 |
EBIT | 142.58 | 462.07 | 766.51 | -1,286 | 377.63 | -454.1 |
EBIT Margin | 0.85% | 2.72% | 4.46% | -6.76% | 2.22% | -2.89% |
Effective Tax Rate | - | 8.47% | 2.36% | - | 12.05% | - |
Revenue as Reported | 16,981 | 16,981 | 17,176 | 19,026 | 16,989 | 15,711 |